Serevent Side Effects and Risks
GlaxoSmithKline’s asthma drug Serevent has been the focus of much concern, and the FDA (Food and Drug Administration), after issuing a Serevent warning, even considered removing it from the U.S. market.
Serevent problems began with a study conducted by GlaxoSmithKline beginning in 1996. The study, called the Salmeterol Multi-center Asthma Research Trial or SMART study, reported so many fatalities that it was stopped early. See Serevent Information and Warnings for more information on the study.
The FDA was concerned by the study results and required updated warnings on Serevent and Advair, another GlaxoSmithKline asthma medication, in 2003, when the first study results were released. The FDA conducted its own review of the SMART study data in 2004, and in 2005 it asked its Pulmonary-Allergy Drugs Advisory Committee to consider whether Serevent and Advair and Foradil, manufactured by Novartis, should be removed from the market.
Suffered harm from Serevent? You may have a lawsuit. Click here, for a top rated law firm to evaluate your legal rights.
In November 2005, the FDA decided to leave Serevent and Advair on the market and to require a black box warning on the dangers of a possible increased worsening of bronchosplasm in Serevent users. In other words, Serevent may make asthma symptoms worse instead of better and asthma-related deaths may be a Serevent side effect. The new labeling was approved in March 2006.
Check out the following articles for more information about Serevent, filing a Serevent lawsuit and finding a Serevent attorney.
Suffered harm from Serevent? You may have a lawsuit. Click here, for a top rated law firm to evaluate your legal rights.